BMO Capital Positive on Horizon Pharma (HZNP) Amid CVS/Caremark News; Affirms at 'Outperform'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
CVS, Express Scripts 2017 Formulary Exclusion Lists Make Waves
August 2, 2016 11:56 AM EDTOn Monday, CVS Health (NYSE: CVS) released its 2017 Standard Formulary Exclusion List and Express Scripts (NASDAQ: ESRX) released its 2017 National Preferred Formulary exclusion list.
Below is a summary of analyst commentary around the list changes:
CVS 2017 Standard Formulary Exclusion List:
Barclays analyst Eric Percher said most notably, CVS signaled aggressively on biosimilars, replacing Neupogen with Zarxio (limited impact under the pharmacy benefit) and Lantus with Basaglar for 2017 (significant impact under the pharmacy benefit)
Percher noted a therapeutics focus on Oncology,... More
Horizon Pharma (HZNP): Contracting Activity Picking Up - Mizuho
August 2, 2016 9:51 AM EDTMizuho Securities analyst, Irina Koffler, reiterated her Outperform rating on shares of Horizon Pharma (NASDAQ: HZNP). The analyst believes that contracting activity is likely to pick up in the back half of the year. Yesterday during market hours, the release of the 2017 Express Scripts exclusion list, followed by the CVS/Caremark... More
Horizon Pharma (HZNP) Says DUEXIS and VIMOVO Will be Covered by CVS/Caremark
August 2, 2016 7:13 AM EDTHorizon Pharma (NASDAQ: HZNP) disclosed the following on Tuesday morning:
Item 7.01 Regulation FD Disclosure.
Horizon Pharma has secured covered status for DUEXIS and VIMOVO with CVS/Caremark. The Company has been informed that beginning January 1, 2017, DUEXIS and VIMOVO will be removed from the CVS/Caremark exclusion list.
... More